Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397345 · ClinicalTrials.gov registry record · Phase 3
TroVax Renal Immunotherapy Survival Trial
A Phase 3 study of Clear Cell Renal Carcinoma, sponsored by Oxford BioMedica.
- Completed
- Registry status
- Phase 3
- Development phase
- 733
- Enrollment target
- 20
- Study locations
NCT00397345 is a Phase 3 study of Clear Cell Renal Carcinoma that has completed, run by Oxford BioMedica. The registered enrollment target is 733 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT00397345, a Phase 3 study of Clear Cell Renal Carcinoma, has completed, sponsored by Oxford BioMedica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 733 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Trovax
- BIOLOGICAL Standard of care therapy
Study Locations (20)
California
- La Jolla, CA - La Jolla
- The Angeles Clinic and Reseach Institute - Los Angeles
- 1300 N. Vermont Ave - Los Angeles
- UCLA Urology/Oncology - Los Angeles
- Scripps Cancer Center - San Diego
- Sharp Health Care - San Diego
Florida
- Broward Oncology Associates - Fort Lauderdale
- SCORE Physician Alliance - St. Petersburg
- SCORE Physician Alliance - St. Petersburg
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Georgia
- Augusta Oncology Associates - Augusta
- SMO-USA Inc. - Canton
Illinois
- Patricia A. Joyce Cancer Institute - Olympia Fields
- Edward H Kaplan and Associates - Skokie
Arizona
- AZ Cancer Center - Tucson
Arkansas
- Little Rock Hematology / Oncology Associates, P.A. - Little Rock
Colorado
- UCHSC - Aurora
District of Columbia
- Washington Cancer Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397345
The ClinicalTrials.gov registry entry for NCT00397345 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 733 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxford BioMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clear Cell Renal Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00397345 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00397345 about?
NCT00397345 is a clinical study titled "TroVax Renal Immunotherapy Survival Trial". The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
What is the current status of trial NCT00397345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 733 participants. The study started on 2006-09. Estimated completion is 2009-12.
What conditions does trial NCT00397345 study?
This clinical trial studies the following conditions: Clear Cell Renal Carcinoma.
What interventions are being tested in trial NCT00397345?
The interventions under investigation include: Placebo (BIOLOGICAL), Trovax (BIOLOGICAL), Standard of care therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00397345?
This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397345 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.